FY 1996 Epidemiologic Research Studies of Acquired Immunodeficiency Syndrome (AIDS) and Human Immunodeficiency Virus (HIV) Infection

Federal RegisterJun 18, 1996

Ask Donna

What actually matters in this document.

Text

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[Announcement Number 625]

FY 1996 Epidemiologic Research Studies of Acquired

Immunodeficiency Syndrome (AIDS) and Human Immunodeficiency Virus (HIV)

Infection

Introduction

The Centers for Disease Control and Prevention (CDC) announces the

availability of fiscal year (FY) 1996 funds for a cooperative agreement

program for epidemiologic and behavioral research studies of AIDS and

HIV infection. These include studies to examine factors related to

disease progression of HIV infection in women, mother-to-child HIV

transmission, sexual and needleborne transmission of HIV among drug

users, and the spread of HIV infection in rural and small cities in the

United States. The study of these research areas as they pertain to

racial and ethnic minority populations (defined as Black, Hispanic,

Asian and Pacific Islander, and American Indian) is encouraged because

minorities constitute over 50% of all reported cases of AIDS and

approximately 76% of all women and children with AIDS.

CDC is committed to achieving the health promotion and disease

prevention objectives of Healthy People 2000, a national activity to

reduce morbidity and mortality and improve the quality of life. This

announcement is related to the priority area of HIV Infection. (To

order a copy of ``Healthy People 2000,'' see the section WHERE TO

OBTAIN ADDITIONAL INFORMATION.)

Authority

This program is authorized under Sections 301(a) and 317(k)(2) of

the Public Health Service Act [42 U.S.C. 241(a) and 247b(k)(2)], as

amended. Applicable program regulations are set forth in 42 CFR Part

52, entitled ``Grants for Research Projects.''

Smoke-Free Workplace

CDC strongly encourages all cooperative agreement recipients to

provide a smoke-free workplace and promote the non-use of all tobacco

products. Public Law 103-227, the Pro-Children Act of 1994, prohibits

smoking in certain facilities that receive Federal funds in which

education, library, day care, health care, and early childhood

development services are provided to children. This is consistent with

the PHS mission to protect and advance the physical and mental health

of American people.

Eligible Applicants

Eligible applicants include all public and private, nonprofit and

for-profit organizations and governments and their agencies. Thus,

universities, colleges, research institutions, hospitals, and other

public and private organizations, State and local governments or their

bona fide agents, federally recognized Indian tribal governments,

Indian tribes or Indian tribal organizations, and small, minority- or

women-owned businesses are eligible to apply.

Note: Organizations described in section 501(c)(4) of the

Internal Revenue Code of 1986 that engage in lobbying are not

eligible to receive Federal grant/cooperative agreement funds.

Availability of Funds

Approximately $6,900,000 will be available in FY 1996 to fund

approximately 16 awards. It is expected that the average new award will

be approximately $300,000 and that the average continuation award will

be $500,000, ranging from $100,000 to $1,000,000. It is expected that

approximately 3 new and 13 competing renewal awards will be made and

that awards will begin on or about September 30, 1996. Awards will be

funded for a 12-month budget period within a project period of up to 5

years. Funding estimates may vary and are subject to change.

Continuation awards within the project period will be made on the basis

of satisfactory programmatic progress and the availability of funds.

Purpose

The purpose of these awards is to help support researchers in the

conduct of HIV-related epidemiologic and behavioral research studies.

These include studies to examine factors related to disease progression

of HIV infection in women, mother-to-child HIV transmission, sexual and

needleborne transmission of HIV among drug users, and the spread of HIV

infection in small cities and rural areas in the United States. The

study of these research areas as they pertain to minority populations

are of special interest.

Research Issues

Four research issues of programmatic interest to the health care

community and to CDC for FY 1996 are listed below and are considered of

significant importance in gaining a greater understanding of the

epidemiology of AIDS and HIV infection. However, applications submitted

by organizations that examine additional important HIV-related

epidemiologic research issues will also be accepted and considered for

funding.

Applicants addressing the same research issue should be willing to

participate in collaborative studies with other CDC-sponsored

researchers, including the use of common data collection instruments,

specimen collection protocols, and data management procedures.

Applicants are required to identify their proposed research issue on

line 1 of the face page of the application if the PHS-398 is used, or

Block 11 of the face page if the PHS-5161-1 is used (for more

information on the forms to use, see the section APPLICATION SUBMISSION

AND DEADLINE).

1. Studies of HIV Disease Progression in Women

Studies should be designed to identify, enroll, and prospectively

follow women who are HIV-infected and demographically similar women who

are not HIV-infected but who have demonstrable risk for HIV infection

so that the biologic, behavioral, and psychosocial determinants and

correlates of HIV disease progression

[[Page 30900]]

and other health outcomes can be assessed. Preference will be given to

sites (1) where at least 200 HIV-infected and 100 HIV-uninfected women

are already being systematically followed, (2) at which behavioral

scientists are part of the research team, and (3) at which the

applicant or its documented collaborative partners have the ability to

perform virologic and immunologic assays. Applicants must demonstrate

that they can provide adequate rates of follow-up, including collection

of laboratory specimens, tracking and abstraction of medical records,

and determination of causes of deaths. Applicants must be willing to

participate in collaborative studies with other CDC-sponsored women's

HIV disease progression projects, including the use of common data

collection instruments, specimen collection protocols, and data

management procedures. Applicants must demonstrate cost-efficient local

data management and statistical capability.

2. Mother-to-Child HIV Transmission Studies

Studies should be designed to identify HIV-infected women during

pregnancy or at delivery and enroll the women and their infants in a

prospective follow-up study to examine factors related to mother-to-

child HIV transmission, early diagnosis of infant infection, and

disease progression in children. Studies designed to examine the effect

of interventions such as zidovudine use to prevent mother-to-child HIV

transmission are of particular interest. Preference will be given to

applicants with studies in which mother-infant pairs are already being

systematically identified and followed, and which have the ability to

perform virologic and immunologic assays. Applicants must demonstrate

that they can provide adequate rates of follow-up of both mothers and

infants, including collection of laboratory specimens at periodic

intervals (particularly within the first 48 hours of birth and during

the first 6 months of life), and long-term follow-up of infants,

including those placed in foster care. Applicants must be willing to

participate in collaborative studies with other CDC-sponsored mother-

to-child HIV transmission projects, including use of common data

collection instruments and study design where warranted. Applicants

must demonstrate cost-efficient data management, laboratory testing,

and statistical capability or provide explicit plans for data

management by CDC or an outside group. Applicants must demonstrate the

ability to enroll and follow at least 30 HIV-positive mother-infant

pairs per year.

3. Sexual and Needleborne Transmission of HIV Among Drug Users

Study proposals are solicited that address HIV infection in young

drug-abusing populations that are recruited on the street and not

routinely seen in clinics, hospitals, or similar institutional

settings. The purpose of such studies will be to address issues

important to the sexual, needleborne, and injection paraphernalia

related transmission of HIV and settings that may contribute to HIV

infection among drug users who are not seen in the usual medical and

drug-treatment facilities. Preference will be given to projects that

involve community outreach to enroll recently initiated drug users for

interview and examination and that focus on inner-city or rural areas

where drug use among young adults is prevalent.

Examples of worthwhile proposals are HIV seroincidence cohorts that

describe initiating practices of injection and risks for young adults;

current sources, acquisition, and cleaning and disposal of needles and

syringes; issues of violence as they relate to drug use and the impact

on individual, family and community; social networks including contacts

and community dynamics that affect HIV incidence. Other related aspects

of incidence and management of infectious complications of drug use,

including skin and respiratory infections that could be altered by HIV

immune suppression, and their possible impact on the progression of HIV

infection. Applicants should demonstrate their ability to access young

injection drug-using populations not currently in drug treatment,

interview and examine them in a confidential manner, and provide or

link study participants to appropriate medical, drug-treatment and

other services. Applicants for studies of these difficult-to-reach

populations should demonstrate their ability to provide new insights

into the epidemiology of HIV infection in injecting drug users and not

duplicate other projects; possess cost-effective data management and

statistical capabilities, or provide specific plans for management of

data; and participate collaboratively in a multisite study with other

researchers in the development, implementation, and analysis of data

from the proposed study.

4. HIV Infection in Small Cities and Rural Areas

Studies should be designed to identify, interview, and learn more

about HIV-infected persons who live in rural and small cities (small

cities and rural areas outside metropolitan statistical areas of more

than 500,000) such as their (1) modes of exposure to HIV, (2) substance

abuse, (3) travel/migration patterns, (4) health care seeking

behaviors, (5) barriers to care, and (6) sexually transmitted diseases.

Preference will be given to studies that address the following

questions. What specific behaviors (e.g., sexual and substance abuse)

are related to infection of persons residing in these areas? Did

persons from these areas become infected in their current areas of

residence or during travel or residences in large metropolitan areas?

What are the barriers to care specific to HIV-infected persons living

in small cities and rural areas? What health care sites (e.g., STD and

family planning clinics) did the patient visit during and before the

estimated time period of infection, and what HIV prevention messages

and services were offered and received?

Applicants must demonstrate the ability to enroll and follow at

least 50 HIV-infected patients residing in small cities and rural

areas. Applicants must be willing to participate collaboratively in a

multi-site study with other researchers in the development,

implementation, and analysis of data from the proposed study.

Applicants are expected to determine proper distribution of

participants by sex, race, and ethnicity for their topic of study and

to state clearly in the application the composition of the proposed

study population. If women, racial, or ethnic minorities are not

included in the proposed study, applicants must justify their

exclusion.

Program Requirements

Under this cooperative agreement program, CDC will assist the

researcher in conducting the epidemiologic research of AIDS and HIV

infection described in the PURPOSE section of this announcement.

In conducting activities to achieve the purpose of this program,

the recipient shall be responsible for the activities listed under

subparagraph 1., below, and CDC shall be responsible for the activities

listed under subparagraph 2., below:

1. Recipient Activities

Applicants addressing the same research issue must be willing to

participate in collaborative studies with other CDC-sponsored

researchers, including the use of common data collection instruments,

specimen collection protocols, and data management procedures.

[[Page 30901]]

a. Meet with other funded grantees and develop the research study

protocol and the interview instrument.

b. Identify, recruit, obtain informed consent from, and enroll an

adequate number of study participants as determined by the study

protocol and the program requirements.

c. Continue to follow study participants as determined by the study

protocol.

d. Establish procedures to maintain the rights and confidentiality

of all study participants.

e. Perform laboratory tests (when appropriate) and data analysis as

determined in the study protocol.

f. Collaborate and share data and specimens (when appropriate) with

other collaborators to answer specific research questions.

g. Conduct data analysis with all collaborators as well as present

research findings subject to the provisions of the following section,

CDC Activities.

2. CDC Activities

a. Provide technical assistance in the design and conduct of the

research.

b. Provide technical guidance in the development of study

protocols, consent forms and questionnaires.

c. Assist in designing a data management system.

d. Perform selected laboratory tests.

e. Coordinate research activities among the different sites.

f. Participate in the analysis of research information and the

presentation of research findings.

Evaluation Criteria

All applications will be reviewed according to the same criteria;

however, applicants will be ranked on a scale of 200 maximum points

according to the four research issues listed above and a fifth category

for all other HIV-related epidemiologic studies. All applicants must

state which research category they are addressing. Applications should

demonstrate the applicant's ability to address the research problem in

a collaborative manner with CDC. Applications will be reviewed and

evaluated based on the evidence submitted, which specifically describes

the applicant's abilities to meet the following criteria:

1. The inclusion of a detailed review of the scientific literature

pertinent to the study being proposed and specific research questions

or hypotheses that will guide the research; (25 points)

2. The originality and need for the proposed research, the extent

to which it does not replicate past or present research efforts, and

how findings will be used to guide prevention and control efforts; (25

points)

3. The quality of the plans to develop and implement the study

describing how study participants (including racial and ethnic minority

populations) will be identified, enrolled, tested and followed; (25

points)

4. The ability to enroll and follow an adequate number of eligible

study participants to ensure proper conduct of the study. This includes

demonstration of the availability of HIV-infected potential study

participants and the experience of the investigator in enrolling and

following such persons in a culturally and linguistically appropriate

manner; the degree to which the applicant has met the CDC Policy

requirements regarding the inclusion of women, ethnic, and racial

groups in the proposed research. This includes:

a. The proposed plan for the inclusion of both sexes and racial and

ethnic minority populations for appropriate representation;

b. The proposed justification when representation is limited or

absent;

c. A statement as to whether the design of the study is adequate to

measure differences when warranted;

d. A statement as to whether the plans for recruitment and outreach

for study participants include the process of establishing partnerships

with community(ies) and recognition of mutual benefits will be

documented; (25 points)

5. The applicant's understanding of the research objectives and the

ability, willingness, and need to collaborate with CDC and researchers

from other study sites in study design and analysis, including use of

common forms, and sharing of specimens (when appropriate) and data; (25

points)

6. The applicant's current experience in AIDS and HIV epidemiologic

or behavioral research and how it will be applied to achieving the

objectives of the study (letters of support from cooperating

organizations that demonstrate the nature and extent of such

cooperation should be included); (20 points)

7. The comprehensiveness of the plan to protect the rights and

confidentiality of all participants; (20 points)

8. Availability of qualified and experienced personnel with

realistic and sufficient percentage-time commitments; clarity of the

described duties and responsibilities of project personnel; adequacy of

the facilities, equipment, and plans for the administration of the

project, including project oversight and data management; (20 points)

9. A comprehensive schedule for accomplishing the activities of the

research and an evaluation plan that identifies methods and instruments

for evaluating progress in designing and implementing the research

objectives. (15 points)

10. Other (Not Scored).

(1) Budget

The budget will be reviewed to determine the extent to which it is

reasonable, clearly justified, consistent with the intended use of

funds, and allowable. All budget categories should be itemized.

(2) Human Subjects

Whether or not exempt from the DHHS regulations, are procedures

adequate for the protection of human subjects? Recommendations on the

adequacy of protections include: (a) protections appear adequate and

there are no comments to make or concerns to raise, or (b) protections

appear adequate, but there are comments regarding the protocol, or (c)

protections appear inadequate and the Objective Review Group (ORG) has

concerns related to human subjects; or (d) disapproval of the

application is recommended because the research risks are sufficiently

serious and protection against the risks are inadequate as to make the

entire application unacceptable.

Funding Preferences

Priority will be given to competing continuation applications from

satisfactorily performing projects over applications for projects not

already receiving support under the program. Projects will be awarded

so that the composite of projects represents the geographic and

demographic characteristics of the HIV-infected population.

Executive Order 12372 Review

Applications are not subject to review under Executive Order 12372,

Intergovernmental Review of Federal Programs.

Public Health System Reporting Requirements

This program is not subject to the Public Health System Reporting

Requirements.

Catalog of Federal Domestic Assistance Number

The Catalog of Federal Domestic Assistance Number is 93.943,

Epidemiologic Research Studies of Acquired Immunodeficiency Syndrome

(AIDS) and Human Immunodeficiency Virus (HIV) Infection in Selected

Population Groups.

[[Page 30902]]

Other Requirements

1. Paperwork Reduction Act

Projects that involve the collection of information from 10 or more

individuals and funded by cooperative agreement will be subject to

review by the Office of Management and Budget (OMB) under the Paperwork

Reduction Act.

2. Human Subjects

This program involves research on human subjects. Therefore, all

applicants must comply with the Department of Health and Human Services

Regulations, 45 CFR Part 46, regarding the protection of human

subjects. Assurance must be provided to demonstrate that the project or

activity will be subject to initial and continuing review by an

appropriate institutional review committee. The applicant will be

responsible for providing assurance in accordance with the appropriate

guidelines and form provided in the application kit.

In addition to other applicable committees, Indian Health Service

(IHS) institutional review committees also must review the project if

any component of IHS will be involved with or support the research. If

any American Indian community is involved, its tribal government must

also approve that portion of the project applicable to it.

3. HIV/AIDS Requirements

Recipients must comply with the document entitled Content of AIDS-

Related Written Materials, Pictorials, Audiovisuals, Questionnaires,

Survey Instruments, and Educational Sessions (June 1992) (a copy is in

the application kit). To meet the requirements for a program review

panel, recipients are encouraged to use an existing program review

panel, such as the one created by the State health department's HIV/

AIDS prevention program. If the recipient forms its own program review

panel, at least one member must be an employee (or a designated

representative) of a State or local health department. The names of the

review panel members must be listed on the Assurance of Compliance form

CDC 0.1113, which is also included in the application kit. The

recipient must submit the program review panel's report that indicates

all materials have been reviewed and approved.

4. Patient Care

Applicants should provide assurance that all HIV-infected patients

enrolled in their studies will be linked to an appropriate local HIV

care system that can address their specific needs such as medical care,

counseling, social services, and therapy. Details of the HIV care

system should be provided, describing how patients will be linked to

the system. Funds will not be made available to support the provision

of direct care for study participants.

5. Women, Racial and Ethnic Minorities

It is the policy of the CDC to ensure that individuals of both

sexes and the various racial and ethnic groups will be included in CDC-

supported research projects involving human subjects, whenever feasible

and appropriate. Racial and ethnic groups are those defined in OMB

Directive No. 15 and include American Indian, Alaskan Native, Asian,

Pacific Islander, Black and Hispanic. Applicants shall ensure that

women, racial and ethnic minority populations are appropriately

represented in applications for research involving human subjects.

Where clear and compelling rationale exist that inclusion is

inappropriate or not feasible, this situation must be explained as part

of the application. This policy does not apply to research studies when

the investigator cannot control the race, ethnicity and/or sex of

subjects. Further guidance to this policy is contained in the Federal

Register, Vol. 60, No. 179, Friday, September 15, 1995, pages 47947-

47951 (a copy is included in the application kit).

Application Submission and Deadline

The original and five copies of the completed application packet

PHS 398 (Revised 5/95, OMB No. 0925-0001) must be submitted to Van

Malone, Grants Management Officer (ATTN: Kevin Moore), Grants

Management Branch, Procurement and Grants Office (625), Centers for

Disease Control and Prevention (CDC), 255 East Paces Ferry Road, NE.,

Room 320, Mail Stop E-15, Atlanta, Georgia 30305, on or before August

2, 1996. States and local governments may use Form PHS-5161-1 (Revised

7/92, OMB No. 0937-0189); however, Form PHS-398 is preferred. If using

Form PHS-5161-1, submit an original and two copies to the address

stated above.

1. Deadline

Applications shall be considered as meeting the deadline if they

are either:

a. Received on or before the stated deadline date; or

b. Sent on or before the deadline date and received in time for

submission to the independent review group. (Applicants must request a

legibly dated U.S. Postal Service postmark or obtain a legibly dated

receipt from a commercial carrier or U.S. Postal Service. Private

metered postmarks shall not be accepted as proof of timely mailing.)

2. Late Applications

Applications that do not meet the criteria in 1.a. or 1.b. above

are considered late applications. Late applications will not be

considered in the current competition and will be returned to the

applicant.

Where to Obtain Additional Information

A complete program description, information on application

procedures, an application package, and business management technical

assistance may be obtained from Kevin Moore, Grants Management

Specialist, Grants Management Branch, Procurement and Grants Office,

Centers for Disease Control and Prevention (CDC), 255 East Paces Ferry

Road, NE., Room 320, Mail Stop E-15, Atlanta, Georgia 30305, telephone

(404) 842-6550, E-mail address [email protected]. The

announcement will be available on one of two Internet sites on the

publication date: CDC's home page at http://www.cdc.gov, or at the

Government Printing Office home page (including free access to the

Federal Register) at http://www.access.gpo.gov.

Programmatic technical assistance may be obtained from Jeff Efird,

Division of HIV/AIDS Prevention, National Center for HIV, STD, TB

Prevention, Centers for Disease Control and Prevention (CDC), 1600

Clifton Road, NE., Mail Stop E-45, Atlanta, Georgia 30333, telephone

(404) 639-6130. Eligible applicants are encouraged to call before

developing and submitting their application. Please refer to

Announcement Number 625 when requesting information.

Potential applicants may obtain a copy of ``Healthy People 2000''

(Full Report, Stock No. 017-001-00474-0) or ``Healthy People 2000''

(Summary report, Stock No. 017-001-00473-1) referenced in the

Introduction from the Superintendent of Documents, Government Printing

Office, Washington, DC 20402-9325, telephone (202) 512-1800.

Dated: June 11, 1996.

Joseph R. Carter,

Acting Associate Director for Management and Operations, Centers for

Disease Control and Prevention (CDC).

[FR Doc. 96-15379 Filed 6-17-96; 8:45 am]

BILLING CODE 4163-18-P

This is a copy of a public record, reproduced as it was published. It is not legal advice, and it may not be the version a court would rely on. Check the official source before you cite it.

A word about cookies

We need a few to keep you signed in and the library working. The rest help us see which pages people use and where they get stuck. They stay off unless you say yes.